The prevention, detection and management of cancer treatment-induced cardiotoxicity: A meta-review

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Conway, Aaron ^a   McCarthy, Alexandra L ^a   Lawrence, Petra ^b   Clark, Robyn A ^c  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

Cancer; Cardiotoxicity; Chemotherapy; Heart failure; Meta review; Systematic review

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CREATINE PHOSPHATE; DOXORUBICIN; ENALAPRIL; EPIRUBICIN; LAPATINIB; PERTUZUMAB; RAZOXANE; TAXANE DERIVATIVE; TRASTUZUMAB; UBIDECARENONE; ANTINEOPLASTIC ANTIBIOTIC;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER THERAPY; CARDIOTOXICITY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHILDHOOD CANCER; CLINICAL DECISION MAKING; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL (TOPIC); DIET SUPPLEMENTATION; DISEASE MARKER; DIZZINESS; DRUG EFFICACY; FATIGUE; FOLLICULAR LYMPHOMA; HEART DEATH; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HUMAN; HYPOTENSION; META ANALYSIS (TOPIC); NONHUMAN; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW (TOPIC); ANIMAL; BIBLIOGRAPHIC DATABASE; DISEASE MANAGEMENT; META ANALYSIS; NEOPLASMS;

ANIMALS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOTOXICITY; DATABASES, BIBLIOGRAPHIC; DISEASE MANAGEMENT; HUMANS; NEOPLASMS;

EID: 84929159079     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1407-6     Document Type: Article

References (41)

1. Stratigos A, Forsea A, Van Der Leest R, et al. Euromelanoma: a dermatologyled European campaign against nonmelanoma skin cancer and cutaneous melanoma. Past, present and future. Br J Dermatol. 2012;167:99-104.
2. Richards M. The national awareness and early diagnosis initiative in England: assembling the evidence. Br J Cancer. 2009;101:S1-4.
3. Fleissig A, Jenkins V, Catt S, Fallowfield L. Multidisciplinary teams in cancer care: are they effective in the UK? Lancet Oncol. 2006;7:935-43.
4. Rachet B, Maringe C, Nur U, et al. Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncol. 2009;10:351-69.
5. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014;15:23-34.
6. Urruticoechea A, Alemany R, Balart J, Villanueva A, Vinals F, Capella G. Recent advances in cancer therapy: an overview. Curr Pharm Des. 2010;16:3-10.
7. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2011;37:300-11.
8. Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol. 2012;23:vii155-vii66.
9. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions Version 5.1.0 [Updated March 2011]. The Cochrane Collaboration. 2011. Available from www.cochrane-handbook.org
10. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011-9.
11. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist. 2008;13:1084-96.
12. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2010;55:213-20.
13. Wells QS, Lenihan DJ. Reversibility of left ventricular dysfunction resulting from chemotherapy: can this be expected? Prog Cardiovasc Dis. 2010;53:140-8.
14. Chargari C, Kirov KM, Bollet MA, et al. Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessment. Cancer Treat Rev. 2011;37:321-30.
15. Lipshultz SE, Franco VI, Miller TL, Colan SD, Sallan SE. Cardiovascular disease in adult survivors of childhood cancer. Annu Rev Med. 2015;66:161-76.
16. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10.
17. Toma M, McAlister FA, Bialy L, Adams D, Vandermeer B, Armstrong PW. Transition from meeting abstract to full-length journal article for randomized controlled trials. J Am Med Assoc. 2006;295:1281-7.
18. Moher D. Epidemiology and reporting characteristics of systematic reviews. PLoS Med. 2007;4:e78.
19. Collaboration TC. Cochrane handbook for systematic reviews of interventions version 5.1. 2011. Available from www.cochrane-handbook.org
20. Shea BJ, Hamel C, Wells GA, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol. 2009;62:1013-20.
21. Qin Y-Y, Li H, Guo X-J, et al. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30,698 patients. PLoS One. 2011;6:e26946.
22. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2007, Issue 4 Art No. CD004421.
23. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153.
24. Valachis A, Nearchou A, Polyzos NP, Lind P. Cardiac toxicity in breast cancer patients treated with dual HER2 blockade. Int J Cancer. 2013;133:2245-52.
25. Lemos Duarte I, da Silveira Nogueira Lima JP, Passos Lima CS, Deeke Sasse A. Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: a systematic review with meta-analysis. Breast. 2012;21:343-9.
26. Lord S, Ghersi D, Gattellari M, Wortley S, Wilcken N, Simes J. Antitumour antibiotic containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2004, Issue 4. Art No. CD003367
27. Shelley M, Harrison C, Coles B, Staffurth J, Wilt TJ, Mason MD. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev. 2006, Issue 4. Art No. CD005247
28. Van Dalen E, Raphaël M, Caron H, Kremer L. Treatment including anthracyclines versus treatment not in-cluding anthracyclines for childhood cancer. Cochrane Database Syst Rev. 2011, Issue 1 Art. No.: CD006647
29. van Dalen EC, Caron HN, Dickinson HO, Kremer LCM. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011, Issue 6 Art No. CD003917
30. van Dalen EC, Michiels E, Caron HN, Kremer L. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010, Issue 5. Art No. CD005006
31. van Dalen EC, Van der Pal H, Caron HN, Kremer L. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev. 2009, Issue 4. Art No. CD005008
32. Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337.
33. Itchaki G, Gafter Gvili A, Lahav M, Vidal L, Raanani P, Shpilberg O, Paul M. Anthracycline containing regimens for treatment of follicular lymphoma in adults. Cochrane Database Syst Rev. 2013, Issue 7. Art. No. CD008909.
34. Roffe L, Schmidt K, Ernst E. Efficacy of coenzyme Q10 for improved tolerability of cancer treatments: a systematic review. J Clin Oncol. 2004;22:4418-24.
35. Bryant J, Picot J, Baxter L, Levitt G, Sullivan I, Clegg A. Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. Br J Cancer. 2007;96:226-30.
36. Bryant J, Picot J, Baxter L, Levitt G, Sullivan I, Clegg A. Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review. Eur J Cancer. 2007;43:1959-66.
37. Sieswerda E, Kremer L, Caron H, van Dalen E. The use of liposomal anthracycline analogues for childhood malignancies: a systematic review. Eur J Cancer. 2011;47:2000-8.
38. Sieswerda E, van Dalen EC, Postma A, Cheuk D, Caron HN, Kremer L. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database Systematic Reviews. 2011; Issue 9: CD008011.
39. van Dalen EC, Caron HN, Kremer L. Prevention of anthracycline-induced cardiotoxicity in children: the evidence. Eur J Cancer. 2007;43:1134-40.
40. Chan R. Two decades of exceptional achievements: does the evidence support nurses to favour Cochrane systematic reviews over other systematic reviews? Int J Nurs Stud. 2012;49:773-4.
41. Scott JM, Khakoo A, Mackey JR, Haykowsky MJ, Douglas PS, Jones LW. Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer current evidence and underlying mechanisms. Circulation. 2011;124:642-50.